Comparative Pharmacology
Head-to-head clinical analysis: PHYRAGO versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHYRAGO versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
PHYRAGO vs PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PHYRAGO is a monoclonal antibody that targets and neutralizes the activity of a specific inflammatory cytokine, thereby inhibiting downstream signaling pathways involved in immune-mediated inflammation.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
200 mg orally twice daily with food.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in adults; may be prolonged in hepatic impairment (up to 15 hours).
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <5% of dose; fecal elimination of metabolites accounts for ~90%.
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic